At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
ExAblate Transcranial Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System
In Brief
A clinical study evaluating ExAblate Transcranial System for Parkinson's Disease. Completed, enrolled 20 participants across 5 sites.
Detailed Summary
The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age and considered medication-refractory with advanced idiopathic Parkinson's disease (PD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartApr 2015
Primary CompletionMay 2019
Study CompletionJul 2019
TodayJul 2026
First PostedOct 13, 2014
Enrollment StartApr 1, 2015
Primary CompletionMay 15, 2019
Study CompletionJul 26, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.7 years ago
Interventions
ExAblate Transcranial Systemdevice
Transcranial MRgFUS